By Laura Lutz
Des Moines, March 21 - Chromos Molecular Systems Inc. arranged a private placement of units for C$4 million.
The company plans to sell 40 million units of one share and one warrant at C$0.10 per unit. Each whole warrant will be exercisable at C$0.15 for five years.
A syndicate led by Dundee Securities Corp. and including Canaccord Capital Corp. will underwrite the deal.
Most of the proceeds will be used to commercialize and expand the company's cell-line engineering business, to repay its bridge loan financing and to develop CHR-1103, its lead product. The rest of the proceeds will be used for working capital and general corporate purposes.
Settlement is expected on April 6.
Based in Burnaby, B.C., Chromos is a biopharmaceutical company focused on inflammatory diseases and thrombotic disorders.
| Issuer: | Chromos Molecular Systems Inc.
|
| Issue: | Units of one share and one warrant
|
| Amount: | C$4 million
|
| Units: | 40 million
|
| Price: | C$0.10
|
| Warrants: | One per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | C$0.15
|
| Underwriters: | Dundee Securities Corp. (lead), Canaccord Capital Corp.
|
| Pricing date: | March 21
|
| Settlement date: | April 6
|
| Stock symbol: | Toronto: CHR
|
| Stock price: | C$0.13 at close March 21
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
